

FORM PTO 449 MAR 15 2004 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. BURNHAM.004A	APPLICATION NO. 10/735,418
	APPLICANT Read et al.	
	FILING DATE December 11, 2003	GROUP Unknown

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
RB	1.	Bohm et al., "The 5'-untranslated region of p23 mRNA from the Ehrlich ascites tumor is involved in translation control of the growth related protein p23" 1991, Biomed Biochim Acta 50:1193; 174:130
	2.	Buolamwini, "Novel anticancer drug discovery" 1999, Curr Opin Chem Biol, 3:500-509
	3.	Cheng et al., "Functional redundancy of Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis" 1997, EMBO J 16:1865
	4.	Cheng et al., "Conversion of Bcl-2 to a Bax-like Death Effector by Caspases" 1997, Science 278:1966-1968
	5.	Degtarev et al., "Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-X _L " 2001, Nat Cell Bio 3:173-182
	6.	Del Bello et al., "Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells" 2001, Oncogene 20:4591-4595
	7.	Enyedy et al., "Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening" 2001, J Med Chem 44:4313-4324
	8.	Fadeel et al., "Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myloid leukemia cells" 1999, Leukemia 13:719-728
	9.	Finnegan et al., "Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions" 2001, Br J Cancer 85:115-121
A	10.	Fujita et al., "Involvement of Bcl-2 Cleavage in the Acceleration of VP-16-Induced U937 Cell Apoptosis" 1998, Biochem Biophys Res Commun 246:484-488

EXAMINER RB Mond	DATE CONSIDERED 11-01-04
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

 <p>FORM PTO-1249</p> <p>MAR 15 2004</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	<p>ATTY. DOCKET NO. BURNHAM.004A</p>	<p>APPLICATION NO. 10735,418</p>
	<p>APPLICANT Reed et al.</p>	
	<p>FILING DATE December 11, 2003</p>	<p>GROUP Unknown</p>

[illegible]

W:\DOCS\JAH\JAH-7156.DOC
031004

EXAMINER <u>RB Ma</u> :	DATE CONSIDERED <u>11-01-04</u>
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	